Clinical Trial Update: Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sorafenib as relapse prophylaxis after hematopoietic cell transplantation using the PTBCy regimen; the study is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: St. Petersburg State Pavlov Medical University | Conditions: Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | Phase 2 | Status: RECRUITING